Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Research & Development data on record, last reported at $21.2 million in Q4 2025.

  • For Q4 2025, Research & Development fell 7.33% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $90.4 million, down 13.14%, while the annual FY2025 figure was $90.4 million, 13.14% down from the prior year.
  • Research & Development reached $21.2 million in Q4 2025 per AMLX's latest filing, up from $19.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $44.9 million in Q4 2023 and bottomed at $6.9 million in Q1 2021.
  • Average Research & Development over 5 years is $23.0 million, with a median of $22.9 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 212.7% in 2022, then plummeted 49.03% in 2024.
  • A 5-year view of Research & Development shows it stood at $13.4 million in 2021, then soared by 70.32% to $22.8 million in 2022, then soared by 96.88% to $44.9 million in 2023, then plummeted by 49.03% to $22.9 million in 2024, then decreased by 7.33% to $21.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $21.2 million in Q4 2025, $19.9 million in Q3 2025, and $27.2 million in Q2 2025.